Edition:
United States

People: Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

3.89USD
11:11am EDT
Change (% chg)

$0.10 (+2.64%)
Prev Close
$3.79
Open
$3.81
Day's High
$3.92
Day's Low
$3.77
Volume
15,618
Avg. Vol
80,862
52-wk High
$14.52
52-wk Low
$3.20

Stead, Paul 

Mr. Paul Stead is Vice President - Business Development of the Company. Paul joins Adaptimmune, most recently, from Inovio Pharmaceuticals, Inc. developing DNA-based immunotherapies within oncology and infectious diseases. Prior to that, he was with Nimbus Therapeutics LLC where he played a key role in Gilead's acquisition of Nimbus's Comprised Acetyl CoA Carboxylase Inhibitors Program for treatment of NASH and related disorders.1 Paul is a scientist by background earning a BSc, then PhD in Pharmaceutical Sciences from Bath and Nottingham Universities in the UK, respectively, after which he joined GlaxoSmithKline plc as a Senior Scientist in Chemistry BioProcess Development. He progressed from R&D in GSK's Natural Product Chemistry Department to lead Competitive and Scientific Intelligence in the US. Subsequently, Paul worked up through technology licensing, and senior business development roles in GSK Worldwide Business Development Transactions and then specifically Platform Technology and Science Business Development.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --